Prime Medicine (PRME) Earnings Date, Estimates & Call Transcripts $3.80 -0.16 (-4.04%) (As of 10/17/2024 ET) Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrends Earnings SummaryUpcoming Earnings DateNov. 1EstimatedActual EPS (Aug. 8) -$0.46 Missed By -$0.06 Consensus EPS (Aug. 8) -$0.40 Earnings Press Release Get Prime Medicine Earnings AlertsEnter your email address below to receive the latest news and earnings results for PRME and its competitors with MarketBeat's FREE daily newsletter. Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenuePRME Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.PRME Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Porter & CompanyElection warning coming true… If you missed it, my emergency election broadcast is now available - watch it before it's too late.Click here to watch it now. Prime Medicine Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20241($0.45)($0.45)($0.45)Q2 20242($0.45)($0.40)($0.43)Q3 20242($0.46)($0.40)($0.43)Q4 20242($0.40)($0.28)($0.34)FY 20247($1.76)($1.53)($1.65)Q1 20252($0.40)($0.28)($0.34)Q2 20252($0.40)($0.28)($0.34)Q3 20252($0.32)($0.27)($0.30)Q4 20252($0.32)($0.27)($0.30)FY 20258($1.44)($1.10)($1.27)PRME Earnings Date and InformationPrime Medicine last released its earnings data on August 8th, 2024. The reported ($0.46) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.40) by $0.06. Prime Medicine has generated ($2.17) earnings per share over the last year (($2.17) diluted earnings per share). Earnings for Prime Medicine are expected to grow in the coming year, from ($1.77) to ($1.46) per share. Prime Medicine has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Friday, November 1st, 2024 based off prior year's report dates.Read More Prime Medicine Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks 11/1/2024(Estimated)------- 8/8/2024-($0.40)($0.46)($0.06)($0.46)-- 5/10/2024Q1 2024($0.45)($0.44)+$0.01($0.44)-$0.59 million 3/1/2024Q4 2023($0.48)($0.56)($0.08)($0.41)-- 11/3/2023Q3 2023($0.45)($0.55)($0.10)($0.55)-- 8/7/2023Q2 2023($0.42)($0.47)($0.05)($0.47)-- 5/11/2023Q1 2023($0.42)($0.44)($0.02)($0.44)-- Get the Latest News and Ratings for PRME and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Prime Medicine and its competitors with MarketBeat's FREE daily newsletter. 3/9/2023Q4 2022($0.77)($0.56)+$0.21($0.56)-- Prime Medicine Earnings - Frequently Asked Questions When is Prime Medicine's earnings date? Prime Medicine has not confirmed its next earnings publication date, but the company's estimated earnings date is Friday, November 1st, 2024 based off last year's report dates. Learn more on PRME's earnings history. Did Prime Medicine beat their earnings estimates last quarter? In the previous quarter, Prime Medicine (NYSE:PRME) missed the analysts' consensus estimate of ($0.40) by $0.06 with a reported earnings per share (EPS) of ($0.46). Learn more on analysts' earnings estimate vs. PRME's actual earnings. How much revenue does Prime Medicine generate each year? Prime Medicine (NYSE:PRME) has a recorded annual revenue of $591,000.00. How much profit does Prime Medicine generate each year? Prime Medicine (NYSE:PRME) has a recorded net income of -$198.13 million. PRME has generated -$2.17 earnings per share over the last four quarters. What is Prime Medicine's EPS forecast for next year? Prime Medicine's earnings are expected to grow from ($1.77) per share to ($1.46) per share in the next year. More Earnings Resources from MarketBeat Related Companies: Recursion Pharmaceuticals Earnings Date Immunocore Earnings Date BioCryst Pharmaceuticals Earnings Date Tarsus Pharmaceuticals Earnings Date Autolus Therapeutics Earnings Date Vir Biotechnology Earnings Date Cullinan Therapeutics Earnings Date CARGO Therapeutics Earnings Date Relay Therapeutics Earnings Date Sana Biotechnology Earnings Date Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles: Taiwan Semiconductor Soars on Earnings With More Room to RunBank of America Earnings Uncover Shifts in Consumer SpendingGoldman Sachs Earnings Reveal Market Moves Investors Can't IgnoreNike’s Post-Earnings Drop Presents a Buying OpportunityMicron Stock Soars as AI Demand Fuels Big Q4 Earnings BeatGameStop: Earnings Won’t Save It, Dilution Points to TroubleIs Merck Stock Undervalued After Its Colossal Earnings Growth? This page (NYSE:PRME) was last updated on 10/17/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredRetire off just one stock ticker?ONE AI Stock is All You Need... There are over 6,000 stocks listed in the market right now. They will NOT m...Behind the Markets | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredAdd $2T of Potential Magic to Your PortfolioRevolutionizing a whole $2T entertainment and licensing industry might sound like the stuff of fairytales. But...Elf Labs | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMassive trading opportunity begins by October 21 October 21 could spark a mania among “next-generation” AI stocks. That’s the newest prediction from a Wall Str...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prime Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Prime Medicine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.